Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia (WM). PATIENTS AND METHODS: Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies)...

Descripción completa

Detalles Bibliográficos
Autores principales: Treon, Steven P., Meid, Kirsten, Gustine, Joshua, Yang, Guang, Xu, Lian, Liu, Xia, Patterson, Christopher J., Hunter, Zachary R., Branagan, Andrew R., Laubach, Jacob P., Ghobrial, Irene M., Palomba, M. Lia, Advani, Ranjana, Castillo, Jorge J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078354/
https://www.ncbi.nlm.nih.gov/pubmed/32931398
http://dx.doi.org/10.1200/JCO.20.00555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078354/
https://www.ncbi.nlm.nih.gov/pubmed/32931398
http://dx.doi.org/10.1200/JCO.20.00555

Ejemplares similares